143 related articles for article (PubMed ID: 36539295)
21. Hepatitis C during disease modifying therapy with Fingolimod for Relapsing Remitting Multiple Sclerosis: diagnosis and treatment.
Aslanyan A; Anwar-Hashim Z; Siripurapu R; Mihalova T
BMJ Case Rep; 2021 Feb; 14(2):. PubMed ID: 33637491
[TBL] [Abstract][Full Text] [Related]
22. Lymphomatoid papulosis: A cutaneous lymphoproliferative disorder in a patient on fingolimod for multiple sclerosis.
Samaraweera AP; Cohen SN; Akay EM; Evangelou N
Mult Scler; 2016 Jan; 22(1):122-4. PubMed ID: 26219664
[TBL] [Abstract][Full Text] [Related]
23. Ventricular tachycardia after initiation of fingolimod.
Elounais F; Aburahma A; Alkotob ML; Al Hadidi S
BMJ Case Rep; 2017 Sep; 2017():. PubMed ID: 28954755
[TBL] [Abstract][Full Text] [Related]
24. Disease reactivation after fingolimod cessation in Multiple Sclerosis patients with pregnancy desire: A retrospective study.
Callens A; Leblanc S; Le Page E; Edan G; Jourdain A; Coustans M; Wiertlewski S; Laplaud D; Videt D; Lallement F; Leray E; Michel L
Mult Scler Relat Disord; 2022 Oct; 66():104066. PubMed ID: 35908450
[TBL] [Abstract][Full Text] [Related]
25. Fingolimod-associated macular oedema.
Jasani KM; Sharaf N; Rog D; Aslam T
BMJ Case Rep; 2017 Jun; 2017():. PubMed ID: 28619738
[No Abstract] [Full Text] [Related]
26. Improvement of macular edema without discontinuation of fingolimod in a patient with multiple sclerosis: A case report.
Akiyama H; Suzuki Y; Hara D; Shinohara K; Ogura H; Akamatsu M; Hasegawa Y
Medicine (Baltimore); 2016 Jul; 95(29):e4180. PubMed ID: 27442641
[TBL] [Abstract][Full Text] [Related]
27. Ventricular arrhythmia in a male MS patient on fingolimod.
van Pesch V; Marchandise S; El Sankari S; Sindic C
Acta Neurol Belg; 2015 Mar; 115(1):77-9. PubMed ID: 24710722
[No Abstract] [Full Text] [Related]
28. BASAL CELL CARCINOMA AND SQUAMOUS CELL CARCINOMA IN A PATIENT TREATED WITH FINGOLIMOD FOR MULTIPLE SCLEROSIS - A CASE REPORT AND LITERATURE REVIEW.
Zięba N; Gębka-Kępińska B; Sowa P
Wiad Lek; 2022; 75(3):735-741. PubMed ID: 35522887
[TBL] [Abstract][Full Text] [Related]
29. Severe dyspnoea with alteration of the diffusion capacity of the lung associated with fingolimod treatment.
Bianco A; Patanella AK; Nociti V; De Fino C; Lucchini M; Savio FL; Rossini PM; Mirabella M
Mult Scler Relat Disord; 2016 Sep; 9():11-3. PubMed ID: 27645336
[TBL] [Abstract][Full Text] [Related]
30. Asymptomatic bradycardia after first fingolimod dose in a pediatric patient with multiple sclerosis - a case report.
Petruzzo M; Lanzillo R
Neurol Sci; 2021 May; 42(Suppl 1):37-39. PubMed ID: 33635428
[TBL] [Abstract][Full Text] [Related]
31. Retinal hemorrhages following fingolimod treatment for multiple sclerosis; a case report.
Ueda N; Saida K
BMC Ophthalmol; 2015 Oct; 15():135. PubMed ID: 26481728
[TBL] [Abstract][Full Text] [Related]
32. A tumefactive demyelinating lesion in a person with MS after five years of fingolimod.
Jeung L; Smits LMG; Hoogervorst ELJ; van Oosten BW; Frequin STFM
Mult Scler Relat Disord; 2020 May; 40():101978. PubMed ID: 32062445
[TBL] [Abstract][Full Text] [Related]
33. Safety and tolerability of fingolimod in patients with relapsing-remitting multiple sclerosis: results of an open-label clinical trial in Italy.
Laroni A; Brogi D; Brescia Morra V; Guidi L; Pozzilli C; Comi G; Lugaresi A; Turrini R; Raimondi D; Uccelli A; Mancardi GL
Neurol Sci; 2017 Jan; 38(1):53-59. PubMed ID: 27757552
[TBL] [Abstract][Full Text] [Related]
34. Five-year results from a phase 2 study of oral fingolimod in relapsing multiple sclerosis.
Izquierdo G; O'Connor P; Montalban X; von Rosenstiel P; Cremer M; de Vera A; Sfikas N; Francis G; Radue EW; Kappos L
Mult Scler; 2014 Jun; 20(7):877-81. PubMed ID: 24293455
[TBL] [Abstract][Full Text] [Related]
35. Fingolimod-related atrioventricular block in paediatric age group with multiple sclerosis: two case reports.
Kum YE; Pamukçu Ö; Canpolat M
Cardiol Young; 2023 Nov; 33(11):2384-2386. PubMed ID: 37170775
[TBL] [Abstract][Full Text] [Related]
36. Early and recurrent macular oedema in a patient treated with fingolimod.
Cifuentes-Canorea P; Nieves-Moreno M; Sáenz-Francés F; Santos-Bueso E
Neurologia (Engl Ed); 2019 Apr; 34(3):206-207. PubMed ID: 27776961
[No Abstract] [Full Text] [Related]
37. A case of dextrocardia following maternal exposure to generic Fingolimod during the first trimester of pregnancy.
Navardi S; Sahraian MA
Mult Scler Relat Disord; 2018 Apr; 21():69-70. PubMed ID: 29474980
[TBL] [Abstract][Full Text] [Related]
38. Effect of Fingolimod-Treatment on Blood Lipid Profiles of Multiple Sclerosis Patients.
Hovi A; Airas L
J Neuroimmune Pharmacol; 2016 Dec; 11(4):611-612. PubMed ID: 27388874
[No Abstract] [Full Text] [Related]
39. Combination of teriflunomide and interferon as follow-up therapy after fingolimod-associated PML.
Fischer-Barnicol B; Oechtering J; Kuhle J; Lorscheider J; Kappos L; Derfuss T
Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33272956
[No Abstract] [Full Text] [Related]
40. The efficacy and safety of fingolimod in patients with relapsing multiple sclerosis: A meta-analysis.
Yang T; Tian X; Chen CY; Ma LY; Zhou S; Li M; Wu Y; Zhou Y; Cui YM
Br J Clin Pharmacol; 2020 Apr; 86(4):637-645. PubMed ID: 31869429
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
